and anti-La/SSB once before or early in pregnancy in women with SLE or SLE-like disorders, Sj√∂gren's syndrome, systemic sclerosis, and rheumatoid arthritis. Given the relative persistence and unchanged titers of these antibodies, we strongly recommend against repeating the test during pregnancy. Patients with scleroderma renal crisis. Most diseasespecific recommendations for RMD pregnancy management focus on presence of underlying SLE or positive aPL. One aspect of disease in systemic sclerosis, however, is of particular importance during pregnancy: the development of scleroderma renal crisis. While effective medications are usually contraindicated during pregnancy due to risk of adverse fetal effects, they should be considered in this unusual and life-threatening circumstance. We strongly recommend use of angiotensin-converting enzyme inhibitor or angiotensin receptor blockade therapy to treat active scleroderma renal crisis in pregnancy, because the risk of maternal or fetal death